All In Biotech

Drug Trial Radar · NCT07760922

Tirofiban Combined With Aspirin in Moderate Ischemic Stroke

Efficacy and Safety of Tirofiban Combined With Aspirin in Moderate Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,168 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,168

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Xinqiao Hospital of ChongqingAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The First Affiliated Hospital of Nanchang University
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ischemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently improved long-term functional outcome. Tirofiban, a selective glycoprotein IIb/IIIa receptor inhibitor, has shown a clinically meaningful trend toward better 90-day functional outcome (mRS 0-1) in prior tirofiban trials, but existing sample sizes were underpowered to detect this difference. TAMIS is a multicenter, randomized, double-blind, placebo-controlled superiority trial in patients with acute moderate ischemic stroke (NIHSS 4-10) within 24 hours of last known well. Eligible patients are randomized 1:1 to tirofiban plus aspirin versus placebo plus aspirin, both on a background of guideline-based standard medical care. The primary efficacy endpoint is the proportion of patients with an excellent functional outcome (mRS 0-1) at 90 days. The primary safety endpoint is symptomatic intracranial hemorrhage within 48 (±12) hours by the Heidelberg criteria.

Conditions

  • Ischemic Stroke, Acute

Interventions

  • TirofibanDrug

    Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban after randomization: 0.4 µg/kg/min for the first 30 minutes, then 0.1 µg/kg/min for a total of 24 hours. Plus guideline-based standard care.

  • Tirofiban-matching placeboDrug

    Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban-matching placebo infusion (0.4 µg/kg/min × 30 min, then 0.1 µg/kg/min × 24 h). Plus guideline-based standard care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with mRS 0-1 at 90 days (%)Time frame: At 90 days after randomization
  2. Symptomatic intracranial hemorrhage within 48 (±12) hours (Heidelberg criteria) (%)Time frame: 48 (±12) hours after randomization

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • The First People's Hospital of Jingdezhen City

    Jingdezhen, Jiangxi, China

  • The First People's Hospital of Jiujiang City

    Jiujiang, Jiangxi, China

  • The First Affiliated Hospital of Gannan Medical University

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.